ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Isosorbide

Also written as “Isosorbide oral solution”, “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)” and “Isobide”.

Its studies are mostly in Hearing Loss · Lymphoma, B-Cell · Meniere Disease, led by 3 companies.

Drug pageIsosorbide: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 1, 20223 company-led studies, 2 open or runningNext primary completion: Jun 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbClonits history only11 open or runningphase 2since Apr 1, 2022Apr 1, 2022Mar 15, 2030phase 2 · NCT05338931
Lotus Pharmaceuticalits history only10 open or runningphase 4since Mar 21, 2016Mar 21, 2016none ahead
Lunan Pharmaceutical Group11 open or runningphase 3since Dec 23, 2024Dec 23, 2024Jun 30, 2027phase 3 · NCT06765993

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lunan Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 3 study in Hearing LossFirst studyNCT06765993 · 234 planned

Ahead

  1. Jun 30, 2027Primary completion: phase 3 study in Hearing LossNCT06765993

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Lunan Pharmaceutical Group leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06765993Hearing Loss3Not yet recruitingJun 30, 2027234

How it is read

Names in the registry

  • “Isosorbide oral solution”, 1 entry
  • “AT101(Anti-CD19 Chimeric Antigen Receptor T cell)”, 1 entry
  • “Isobide”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.